GSK resubmits drug application for Spero's antibiotic treatment Dec 19, 2025 08:01AM
SmartPros Ltd. (SPRO) Tops Q3 EPS by 26c, Misses on Revenue Nov 13, 2025 04:18PM
SmartPros Ltd. (SPRO) Tops Q2 EPS by 54c Aug 12, 2025 04:02PM
Spero Therapeutics (SPRO) call put ratio 4.8 calls to 1 put with a focus on June and July 2.5 calls May 28, 2025 02:22PM
Spero Therapeutics (SPRO) and GSK (GSK) Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy May 28, 2025 07:01AM


May 13, 2025 04:02PM SmartPros Ltd. (SPRO) Tops Q1 EPS by 2c
Apr 28, 2025 04:01PM Spero Therapeutics (SPRO) Appoints Esther Rajavelu as CEO
Mar 27, 2025 04:03PM SmartPros Ltd. (SPRO) Misses Q4 EPS by 2c
Jan 10, 2025 07:07AM Spero Therapeutics (SPRO) Provides Business Update and Announces Interim Leadership Changes
Dec 2, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Spero Therapeutics (SPRO)
Nov 18, 2024 02:44AM TD Cowen Downgrades Spero Therapeutics (SPRO) to Hold
Nov 14, 2024 04:09PM SmartPros Ltd. (SPRO) Tops Q3 EPS by 18c
Nov 4, 2024 06:47AM Spero Therapeutics (SPRO) PT Lowered to $5 at H.C. Wainwright
Oct 29, 2024 04:06PM Spero Therapeutics (SPRO) Reports SPR720 Phase 2a Interim Results, Provides a Business Update
Oct 16, 2024 04:06PM Spero Therapeutics (SPRO) Presents SPR719 In Vitro Data Demonstrating Low Propensity for the Development of Resistance
Oct 3, 2024 07:02AM H.C. Wainwright Reiterates Buy Rating on Spero Therapeutics (SPRO)
Oct 2, 2024 04:31PM Spero Therapeutics (SPRO) Announces Publication of SPR720 Phase 1 Lung Exposure Data
Aug 6, 2024 07:22AM TD Cowen Upgrades Spero Therapeutics (SPRO) to Buy
Aug 5, 2024 04:03PM SmartPros Ltd. (SPRO) Tops Q2 EPS by 5c